Intellia Therapeutics Inc.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

63.42%

Market Cap

2.25 Bil.

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-3.38 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE13.24 G0 Units
PRICE DETERMINATION TIME06/19/2026 / 06:34:48 PM
DAILY VOLUME (UNITS)1,690
DAILY HIGH / LOW13.5413.22
PREV. DAY'S PRICE13.6 (06/18)
CHANGE DAY BEFORE
-0.36
-2.65 %
52 WEEK HIGH / LOW24.17 (10/20)6.922 (11/21)
More Price Information

Key Figures (in EUR)

2027e2026e202520242023
EARNINGS PER SHARE-2.21-2.82-3.38-4.85-5.01
DIVIDENDS PER SHARE0.000.000.000.000.00
DIVIDEND YIELD IN %--0.00 %0.00 %0.00 %
DIVIDEND GROWTH IN %-----
PRICE - EARNINGS RATIO-----
PRICE - BOOK RATIO--1.561.362.70
PRICE - SALES RATIO--14.4019.9174.61
PRICE - CASH FLOW RATIO-----
Further Key Figures

Master Data

WKN
A2AG6H
ISIN
US45826J1051
SYMBOL
38I
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
INTELLIA THERAPEU DL-,01
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
US Dollar
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
96.11 Mil.
MARKET CAPITALISATION
2.25 Bil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
27.10 %
24.77 %
17.85 %
83.78 %
63.42 %
-67.70 %
-78.54 %
75.21 %
HIGH14.2214.2215.2815.2824.1743.20160.0515.28
LOW10.3810.2610.087.496.925.445.447.59
Dividend
per share
INTELLIA THERAPEU DL-,01 does not deliver dividend information

Company profile

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.